Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Rohini Raghavan"'
Autor:
Madhumathy G Nair, Jyothi S Prabhu, Aruna Korlimarla, Savitha Rajarajan, Hari P S, Roma Kaul, Annie Alexander, Rohini Raghavan, Srinath B S, Sridhar T S
Publikováno v:
Cancer Medicine, Vol 9, Iss 15, Pp 5587-5597 (2020)
Abstract Despite the established benefits of long‐term endocrine therapy, women with hormone receptor‐positive breast cancer remain at risk for late relapse. The basis of this is multi‐factorial including genetic, epigenetic, and host factors.
Externí odkaz:
https://doaj.org/article/d281539aef50475f878fc177e406e04d
Autor:
Jyothi S Prabhu, Aruna Korlimarla, C E Anupama, Annie Alexander, Rohini Raghavan, Roma Kaul, Krisha Desai, Savitha Rajarajan, Suraj Manjunath, Marjorrie Correa, R Raman, Anjali Kalamdani, MSN Prasad, Shekar Patil, K S Gopinath, B S Srinath, T.S. Sridhar
Publikováno v:
Translational Oncology, Vol 10, Iss 4, Pp 699-706 (2017)
Hormone receptor positive (HR+) breast cancers are a heterogeneous class with differential prognosis. Although more than half of Indian women present with advanced disease, many such patients do well. We have attempted identification of biologically
Externí odkaz:
https://doaj.org/article/88eb56b8ee9d43b4bbc5476f72e7284b
Autor:
Srinath B S, Aruna Korlimarla, Hari P S, Sridhar T S, Roma Kaul, Annie Alexander, Rohini Raghavan, Madhumathy G. Nair, Jyothi S. Prabhu, Savitha Rajarajan
Publikováno v:
Cancer Medicine
Cancer Medicine, Vol 9, Iss 15, Pp 5587-5597 (2020)
Cancer Medicine, Vol 9, Iss 15, Pp 5587-5597 (2020)
Despite the established benefits of long‐term endocrine therapy, women with hormone receptor‐positive breast cancer remain at risk for late relapse. The basis of this is multi‐factorial including genetic, epigenetic, and host factors. In this s
Autor:
Aruna Korlimarla, Msn Prasad, Rohini Raghavan, Suraj Manjunath, C E Anupama, N Raman, Anjali Kalamdani, Nandini Dendukuri, Annie Alexander, Krisha Desai, Jyothi S. Prabhu, T. S. Sridhar, Kodaganur S. Gopinath, M Correa, B.S. Srinath
Publikováno v:
Journal of Cancer
Background: The 2010 guidelines by ASCO-CAP have mandated that breast cancer specimens with ≥1% positively staining cells by immunohistochemistry should be considered Estrogen Receptor (ER) positive. This has led to a subclass of low-ER positive (1
Autor:
Jyothi S. Prabhu, Roma Kaul, Savitha Rajarajan, S. Rakesh, A Korlimarla, Madhumathy G. Nair, Ss. Tirumalai, Rohini Raghavan, P.S. Hari, Annie Alexander, Msn Prasad, B.S. Srinath, M Correa
Publikováno v:
Cancer Research. 79:P6-05
Introduction Although endocrine therapy has improved the survival of patients with hormone receptor (HR) positive breast cancer considerably, patients with weaker HR expression tend to have poorer outcomes. There exists significant intra tumoral hete
Autor:
S Shivananda, Jyothi S. Prabhu, Suraj Manjunath, N Raman, A Korlimarla, B.S. Srinath, Rohini Raghavan, Annie Alexander, M Correa, Kodaganur S. Gopinath, T.S. Sridhar, Msn Prasad
Publikováno v:
Cancer Research. 73:P6-08
Introduction: Breast cancer is the leading cancer diagnosed in urban Indian women. Historically the proportion of women presenting with advanced disease has been in excess of 50% at most regional cancer centres. The past 20 years has witnessed rapid